HHS Proposes Clinical Trial Reform To Catch Chinese Biotech Sector

The United States Department of Health and Human Services (HHS) has introduced a proposal aimed at reforming clinical trials in response to China's rapidly growing biotechnology sector. The initiative, announced on June 23, seeks to enhance the U.S. position in the competitive biotech field.

The proposed reforms are designed to accelerate the clinical trial process in the U.S., allowing for faster development and approval of new medical treatments. This move highlights the increasing focus on biotechnology as a key area of global competition between the U.S. and China.